ScholarIQanswers from OpenAlex

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer

PaperCitations, authors & open-access status

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer is a paper indexed in ScholarIQ from OpenAlex.

How many citations does IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer have?

ScholarIQcitation count

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer has 548 citations in the OpenAlex counts ScholarIQ stores.

When was IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer published?

ScholarIQyear

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer has 2016 year in the ScholarIQ index.

What is the open-access status of IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer?

ScholarIQoa status

IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer has bronze oa status in the ScholarIQ index.

What is the DOI of IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer?

ScholarIQdoi

The DOI for IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer is on the source record.

What is the PMID of IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer?

ScholarIQpmid

The PMID for IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer is on the source record.

What is the OpenAlex record for IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer?

ScholarIQopenalex

The OpenAlex for IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer is on the source record.

Related on ScholarIQ

470M+ articles · 14-day free trial